Behavior disorders in persons with mental retardation receiving antipsychotic medication

Research in Developmental Disabilities

Volumn 19, Issue 2, 1998, Pages 123-130

  Ono, Yoshiro ^a  

^a Wakayama Pref Children/Disabled P   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHLORPROMAZINE; HYPNOTIC SEDATIVE AGENT; METHYLPHENIDATE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BEHAVIOR DISORDER; CHILD; CONTROLLED STUDY; DISABILITY; DOSE RESPONSE; FEMALE; HUMAN; HYPERACTIVITY; IRRITABILITY; JAPAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; RATING SCALE; RESIDENTIAL HOME;

ADOLESCENT; ADULT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERKINESIS; INSTITUTIONALIZATION; JAPAN; MALE; MENTAL RETARDATION; MIDDLE AGED; SOCIAL BEHAVIOR DISORDERS;

EID: 0031953358     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-4222(97)00046-2     Document Type: Article

References (23)

1. Aman M. G., Burrow W. H., Wolford P. L. The Aberrant Behavior Checklist - Community Factor validity and effect of subject variables for adults in group home . American Journal on Mental Retardation. 100:1995;283-292.
2. Aman M. G., Richmond G., Stewart A. W., Bell J. C., Kissel R. C. The Aberrant Behavior Checklist Factor structure and the effect of subject variables in American and New Zealand facilities . American Journal of Mental Deficiency. 91:1987;570-578.
3. Aman M. G., Sarphare G., Burrow W. H. Psychotropic drugs in group homes Prevalence and relation to demographic/psychiatric variables . American Journal on Mental Retardation. 99:1995;500-509.
4. Aman M. G., Singh N. N. Aberrant Behavior Checklist - Community: Supplementary manual. 1994;Slosson Educational Publication, East Aurora, NY.
5. Aman M. G., Singh N. N., Stewart A. W., Field C. J. The Aberrant Behavior Checklist A behavior rating scale for the assessment of treatment effects . American Journal of Mental Deficiency. 89:1985;485-491.
6. American Association on Mental Retardation. (1992). Mental retardation: Definition, classification and systems of supports (9th ed. pp. 51-60). Washington, DC: Author.
7. Branford D. A study of the prescribing for people with learning disabilities living in the community and in National Health Service care. Journal of Intellectual Disability Research. 38:1994;577-586.
8. Branford D., Collacott R. A., Thorp C. The prescribing of neuroleptic drugs for people with learning disabilities living in Leicestershire. Journal of Intellectual Disability Research. 39:1995;495-500.
9. Briggs R. Monitoring and evaluating psychotropic drug use for persons with mental retardation A follow-up report . American Journal on Mental Retardation. 93:1989;633-639.
10. Buck J. A., Sprague R. L. Psychotropic medication of mentally retarded residents in community long-term care facilities. American Journal on Mental Retardation. 93:1989;618-623.
11. Burd L., Fisher W., Vesely B. N., Williams M., Kerbeshian J., Leech C. Prevalence of psychoactive drug use among North Dakota group home residents. American Journal on Mental Retardation. 96:1991;119-126.
12. Clarke D. J., Kelly S., Thinn K., Corbett J. A. Psychotropic drugs and mental retardation 1. Disabilities and the prescription of drugs for behavior and for epilepsy in three residential settings . Journal of Mental Deficiency Research. 34:1990;385-395.
13. Davis J. M. Organic therapies Antipsychotic drugs . Freeman A. H., Kaplan H. I., Sadock B. J. Comprehensive textbook of psychiatry. 3rd ed. 1980;2257-2289 Williams & Wilkins, Baltimore.
14. Intagliata J., Rinck C. Psychoactive drug use in public and community residential facilities for mentally retarded persons. Psychopharmacology Bulletin. 21:1985;268-278.
15. Jacobson J. W. Problem behavior and psychiatric impairment within a developmentally disabled population. III Psychotropic medication . Research in Developmental Disabilities. 9:1988;23-38.
16. Kiernan C., Reeves D., Alborz A. The use of antipsychotic drugs with adults with learning disabilities and challenging behaviour. Journal of Intellectual Disability Research. 39:1995;263-274.
17. Ono Y. Factor validity and reliability for the Aberrant Behavior Checklist - Community in the Japanese population with mental retardation. Research in Developmental Disabilities. 17:1996;303-309.
18. Poindexter A. R. Psychotropic drug patterns in a large ICF/MR facility A ten-year experience . American Journal on Mental Retardation. 93:1989;624-626.
19. Schaar D. W., Hackenberg T. Toward a functional analysis of drug treatment for behavior problems of people with developmental disabilities. American Journal on Mental Retardation. 99:1994;123-140.
20. Singh N. N., Ellis C. R., Donatelli L. S., Williams D. E., Ricketts R. W., Goza A. B., Perlman N., Everly D. E., Best A. M., Singh Y. N. Professionals' perceptions of psychotropic medication in residential facilities for individuals with mental retardation. Journal of Intellectual Disability Research. 40:1996;1-7.
21. Stone R. K., Alvarez W. F., Ellman G., Hom A. C., White J. F. Prevalence and prediction of psychotropic drug use in California developmental centers. American Journal on Mental Retardation. 93:1989;627-632.
22. Sturmey P. Diagnostic-based pharmacological treatment of behavior disorders in persons with developmental disabilities A review and decision-making typology . Research in Developmental Disabilities. 16:1995;235-252.
23. Wressell S. E., Tyrer S. P., Berney T. P. Reduction in antipsychotic drug dosage in mentally handicapped patients A hospital study . British Journal of Psychiatry. 157:1990;101-106.